Key facts
- Notable investors include Auckland UniServices.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for OleQuat
- ·The full record, as it builds
Funding rounds
No funding rounds for OleQuat are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OleQuat
Developer of advanced antimicrobial chemical compounds designed to deliver broad-spectrum pathogen activity with improved safety and reduced environmental persistence. The company focuses on the research and development of patent-protected olefinic quaternary ammonium compounds with anti-biofilm properties, formulates these next-generation agents for potential use as low-dose preservatives and high-performance surface sanitisers, and advances preclinical validation and regulatory readiness, enabling healthcare, industrial, and consumer product developers to adopt safer antimicrobial chemistries with flexible application potential.
- Sector
- Materials and Resources
- HQ
- Auckland, New Zealand
- Founded
- 2025
- Employees
- 2
- Website
- olequat.com/
- Ownership
- Privately Held (backing)
OleQuat doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OleQuat shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OleQuat in its N-PORT filings yet. We sweep new filings monthly.